Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$38.28 USD
+0.13 (0.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $38.24 -0.04 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Rhythm Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 276 | 333 | 295 | 173 | 292 |
Receivables | 15 | 6 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 9 | 3 | 0 | 0 | 0 |
Other Current Assets | 9 | 12 | 13 | 9 | 10 |
Total Current Assets | 308 | 354 | 308 | 182 | 302 |
Net Property & Equipment | 1 | 2 | 3 | 3 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 7 | 8 | 5 | 0 | 0 |
Deposits & Other Assets | 15 | 17 | 12 | 0 | 0 |
Total Assets | 333 | 382 | 330 | 187 | 309 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 6 | 5 | 10 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 48 | 33 | 30 | 13 | 14 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 7 | 0 | 0 |
Total Current Liabilities | 55 | 40 | 43 | 18 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 106 | 76 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 163 | 118 | 45 | 21 | 28 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,064 | 974 | 813 | 626 | 606 |
Retained Earnings | -895 | -710 | -529 | -459 | -325 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 170 | 264 | 284 | 167 | 281 |
Total Liabilities & Shareholder's Equity | 333 | 382 | 330 | 187 | 309 |
Total Common Equity | 170 | 264 | 284 | 167 | 281 |
Shares Outstanding | 59.10 | 56.30 | 50.20 | 44.20 | 43.90 |
Book Value Per Share | 2.87 | 4.69 | 5.66 | 3.77 | 6.40 |
Fiscal Year End for Rhythm Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 276 | 299 | 254 | 295 |
Receivables | NA | 15 | 15 | 14 | 8 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 9 | 8 | 6 | 5 |
Other Current Assets | NA | 9 | 8 | 10 | 10 |
Total Current Assets | NA | 308 | 329 | 284 | 318 |
Net Property & Equipment | NA | 1 | 2 | 2 | 2 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 7 | 7 | 7 | 8 |
Deposits & Other Assets | NA | 15 | 15 | 16 | 17 |
Total Assets | NA | 333 | 354 | 310 | 346 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 4 | 8 | 13 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 48 | 44 | 36 | 31 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 1 | 1 |
Total Current Liabilities | NA | 55 | 50 | 46 | 46 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 106 | 105 | 79 | 78 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 163 | 157 | 128 | 126 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,064 | 1,051 | 991 | 982 |
Retained Earnings | NA | -895 | -853 | -809 | -762 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 170 | 197 | 182 | 220 |
Total Liabilities & Shareholder's Equity | NA | 333 | 354 | 310 | 346 |
Total Common Equity | 0 | 170 | 197 | 182 | 220 |
Shares Outstanding | 60.10 | 59.10 | 56.90 | 56.90 | 56.80 |
Book Value Per Share | 0.00 | 2.87 | 3.47 | 3.20 | 3.87 |